MX2019013327A - Formulación para administración ocular de fármacos. - Google Patents

Formulación para administración ocular de fármacos.

Info

Publication number
MX2019013327A
MX2019013327A MX2019013327A MX2019013327A MX2019013327A MX 2019013327 A MX2019013327 A MX 2019013327A MX 2019013327 A MX2019013327 A MX 2019013327A MX 2019013327 A MX2019013327 A MX 2019013327A MX 2019013327 A MX2019013327 A MX 2019013327A
Authority
MX
Mexico
Prior art keywords
drug delivery
ocular drug
delivery formulation
formulation
ocular
Prior art date
Application number
MX2019013327A
Other languages
English (en)
Inventor
Sazzad Hossain
Maryam Kabiri
Vikramaditya Ganapati Yadav
Original Assignee
Inmed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmed Pharmaceuticals Inc filed Critical Inmed Pharmaceuticals Inc
Publication of MX2019013327A publication Critical patent/MX2019013327A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona una formulación de suministro de fármacos oculares que comprende un vehículo de suministro que comprende un polímero celulósico y un polisacárido aniónico y nanopartículas que comprenden un copolímero de bloque anfifílico no ionizable y un cannabinoide. La formulación tiene un punto de gel de aproximadamente 30 ° C a aproximadamente 37 ° C.
MX2019013327A 2017-05-08 2018-05-08 Formulación para administración ocular de fármacos. MX2019013327A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762503258P 2017-05-08 2017-05-08
PCT/CA2018/050548 WO2018205022A1 (en) 2017-05-08 2018-05-08 Ocular drug delivery formulation

Publications (1)

Publication Number Publication Date
MX2019013327A true MX2019013327A (es) 2020-07-27

Family

ID=64104146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013327A MX2019013327A (es) 2017-05-08 2018-05-08 Formulación para administración ocular de fármacos.

Country Status (9)

Country Link
US (1) US12083229B2 (es)
EP (1) EP3621656B1 (es)
JP (1) JP7323458B2 (es)
KR (1) KR20200019864A (es)
CN (1) CN110997006A (es)
AU (1) AU2018266262B2 (es)
CA (1) CA3062904A1 (es)
MX (1) MX2019013327A (es)
WO (1) WO2018205022A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112969452A (zh) 2018-04-09 2021-06-15 艾乐文特科学公司 用于治疗动物疼痛的大麻提取物
CA3106476A1 (en) * 2018-07-10 2020-01-16 Cardinal Advisory Limited Formulation of cannabinoid compounds
GB2579179A (en) * 2018-11-21 2020-06-17 Gw Res Ltd Cannabidiol-type cannabinoid compound
WO2020176547A1 (en) 2019-02-25 2020-09-03 Ginkgo Bioworks, Inc. Biosynthesis of cannabinoids and cannabinoid precursors
EP3958856A4 (en) * 2019-04-24 2023-01-25 Inmed Pharmaceuticals Inc. COMPOSITIONS AND METHODS OF USE OF CANNABINOIDS FOR NEUROPROTECTION
KR20220088726A (ko) * 2019-10-24 2022-06-28 데니스 이. 라봄바드 안구 장치 및 약물 전달 시스템, 및 케이스
WO2021232156A1 (en) * 2020-05-19 2021-11-25 Amacathera Inc. Cannabinoid pharmaceutical composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4263456B2 (ja) * 2002-03-18 2009-05-13 わかもと製薬株式会社 ヒアルロン酸含有熱ゲル化製剤
US9205046B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Enhanced stability of inverse thermal gelling composite hydrogels
US8758826B2 (en) * 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
KR102373259B1 (ko) * 2012-05-03 2022-03-17 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
CN103040888A (zh) * 2013-01-13 2013-04-17 段亚东 一种眼外用制剂及其制备方法和用途
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
CA3039413A1 (en) 2016-10-11 2018-04-19 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
WO2018205038A1 (en) 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling

Also Published As

Publication number Publication date
AU2018266262A1 (en) 2019-11-28
KR20200019864A (ko) 2020-02-25
WO2018205022A1 (en) 2018-11-15
US20200163900A1 (en) 2020-05-28
EP3621656A4 (en) 2021-01-27
CN110997006A (zh) 2020-04-10
CA3062904A1 (en) 2018-11-15
AU2018266262B2 (en) 2022-10-06
EP3621656A1 (en) 2020-03-18
US12083229B2 (en) 2024-09-10
JP2020519604A (ja) 2020-07-02
JP7323458B2 (ja) 2023-08-08
EP3621656B1 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
MX2019013327A (es) Formulación para administración ocular de fármacos.
SG10201808743VA (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
EP4279064A3 (en) Drug delivery from hydrogels
MY167777A (en) A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site
PH12019501199A1 (en) Calcium lactate compositions and methods of use
UA118479C2 (uk) Міцелярний нанокомплекс
WO2017091739A8 (en) Topical film-forming spray
MX359170B (es) Composiciones y metodos para tratar el cabello.
PH12017501371A1 (en) Pressure-sensitive adhesives for transdermal drug delivery
EA201690967A1 (ru) Глазное устройство
MA40473A (fr) Dispositifs d'administration de médicaments à base d'une silicone catalysée par du platine, et leurs procédés d'utilisation
MX2017003561A (es) Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos.
GB2528421A (en) Methods and processes for application of drug delivery polymeric coatings
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
NZ739801A (en) Penflufen polymer particles
MX2018000021A (es) Composiciones multifasicas.
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
EP3284474A4 (en) Polyion complex of poly(l-arginine) segment-containing block copolymer and polyanionic polymer
WO2017181099A8 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
NZ756307A (en) Formulations of cannabinoids for the treatment of acne
EA201890703A1 (ru) Коллоидные частицы, предназначенные для применения в медицине
WO2018236090A3 (ko) 키토산-플루로닉 복합체 및 이를 포함하는 나노운반체
MX2022001772A (es) Formulaciones de isotretinoina y usos y metodos de las mismas.
WO2018151827A8 (en) Kits and methods of using hyaluronidase to modify polysaccharide fillers and delivery systems
MX2017011349A (es) Fluidos de silicona oligomericos/polimericos para uso en sistemas transdermicos de suministro de farmaco.